Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Radom College · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · +7 more institutions
Abstract
The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In a 12-month, randomised, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 yrs, mean forced expiratory volume in one second (FEV1) 36% predicted normal), patients received two inhalations twice daily of either budesonide/formoterol (Symbicort) 160/4.5 microg (delivered dose), budesonide 200 microg (metered dose), formoterol 4.5 microg or placebo. Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of…
Citation impact
- FWCI
- 64.62
- Percentile
- 100%
- References
- 34
Authors
8- WSW SzafrańskiCorresponding
Radom College
- ACAlberto Cukier
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, State Key Laboratory of Respiratory Disease, Tecnológico de Monterrey
- ASAna Sofia Ramírez
AstraZeneca (Sweden), State Key Laboratory of Respiratory Disease
- GMGuillermo Menga
Hospital Fernández
- RHRaúl H. Sansores
Instituto Nacional de Enfermedades Respiratorias
Topics & keywords
- Medicine
- Budesonide
- Formoterol
- Pulmonary disease
- Budesonide/formoterol
- Intensive care medicine
- Internal medicine
- Asthma
- Good health and well-being